References
- Keyhani S, Wang S, Hebert P, Carpenter D, Anderson G. US pharmaceutical innovation in an international context. Am J Public Health. 2010;100(6):1075–1080. doi:10.2105/AJPH.2009.178491.
- Ziccardi L, Cordeddu V, Gaddini L, et al. Gene therapy in retinal dystrophies. Int J Mol Sci. 2019; 20(22):5722. Published 2019 Nov 14. doi:10.3390/ijms20225722.
- Mullard A. 2010 FDA drug approvals. Nat Rev Drug Discov. 2011;10(2):82–85. doi:10.1038/nrd3370.
- Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51. doi:10.1038/nbt.2786.
- Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89(2):183–188. doi:10.1038/clpt.2010.286.
- Gower NJD, Barry RJ, Edmunds MR, Titcomb LC, Denniston AK. Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmol. 2016;16:11. doi:10.1186/s12886-016-0188-2.
- Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed December 31 2019.
- Manual of Policies and Procedures. Center for drug evaluation and research. https://www.fda.gov/files/about%20fda/published/Review-Designation-Policy–Priority-%28P%29-and-Standard-%28S%29.pdf. Accessed April 1, 2020
- Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today. 2012;17(19–20):1088–1102. doi:10.1016/j.drudis.2012.05.007.
- Prescription Drug User Fee Act (PDUFA). U.S. Food and Drug Administration. https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments. Accessed April 1, 2020.
- Herper M. The Cost Of Creating A New Drug Now $5 Billion, Pushing Big Pharma To Change. Forbes; https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/#5b7aee5913c3 Published March 24, 2016. Accessed March 25, 2020..
- Designating an Orphan Drug or Biologic. U.S. food and drug administration. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products. Accessed March 25, 2020.
- O’Connor DJ, Sheean ME, Hofer MP, et al. Defining orphan conditions in the context of the European orphan regulation: challenges and evolution. Nat Rev Drug Discov. 2019;18(7):479–480. doi:10.1038/nrd.2018.128.
- Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041–2044. doi:10.1016/S0140-6736(08)60873-9.
- FDA’s Orphan Drug Modernization Plan. U.S. Food and Drug Administration. https://www.fda.gov/media/106012/download. Published June 29, 2017. Accessed March 25, 2020.
- Wellman-Labadie O, Zhou Y. The US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95(2–3):216–228. doi:10.1016/j.healthpol.2009.12.001.
- Durezol Summary Review. Center for drug research and evaluation. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022212s000_SumR.pdf. Accessed April 1, 2020.
- Orphan Drug Designations and Approvals. accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=265608. Accessed April 8, 2020.
- TissueBlue Summary Review. Center for Drug Research and Evaluation. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209569Orig1s000SumR.pdf. Accessed April 1, 2020.
- Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada and developing countries. Health Law J. 2004;12:183–200.
- Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106–123. doi:10.1089/jop.2012.0200.
- Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146(6):813–8.e1. doi:10.1016/j.ajo.2008.06.004.
- Burris JF, Puglisi JT. Impact of federal regulatory changes on clinical pharmacology and drug development: the common rule and the 21st century cures act. J Clin Pharmacol. 2018;58(3):281–285. doi:10.1002/jcph.1026.
- 21st Century Cures Act. U.S. food and drug administration. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act. Accessed March 31, 2020.
- Kesselheim AS, Avorn J. New “21st century cures” legislation: speed and ease vs science. JAMA. 2017;317(6):581–582. doi:10.1001/jama.2016.20640.